NCPA Statement on PBM Reform: Congressional Inaction Will be Final Nail for Some Community Pharmacies
Pharmacy Times
MARCH 6, 2024
The National Community Pharmacists Association issued a statement on behalf of CEO B. Douglas Hoey.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Pharmacy Times
MARCH 6, 2024
The National Community Pharmacists Association issued a statement on behalf of CEO B. Douglas Hoey.
Pharmacy Times
MARCH 6, 2024
The device conducts blood biomarker tests that accurately diagnose amyloid pathology and can assist in diagnosing Alzheimer disease in patients with cognitive impairment.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
MARCH 6, 2024
They also compared the approach of the European Medicines Agency and the FDA in drug approvals.
Pharmacy Times
MARCH 6, 2024
Vitamin D preserved insulin-producing cells and cell function, which can reduce complications in young patients.
Pharmacy Times
MARCH 6, 2024
Diabetes is a known risk factor for cognitive decline and small vessel disease.
Pharmacy Times
MARCH 6, 2024
This episode highlights how celebrity endorsements and local influencers can be leveraged to address vaccine hesitancy by shaping attitudes, but also must account for factors like audience trust and the potential for both benefits and limitations.
Pharmacy Times
MARCH 5, 2024
Investigators also found that those with community-acquired, radiology-confirmed pneumonia with lower respiratory tract infections had worse outcomes.
Pharmacy Times
MARCH 5, 2024
Denosumab-bbdz (Wyost; Sandoz) and denosumab-bbdz (Jubbonti; Sandoz) are approved as interchangeable for all indications of Xgeva (denosumab; Amgen) and Prolia (denosumab; Amgen).
Pharmacy Times
FEBRUARY 16, 2024
Tigilanol tiglate is a novel, small molecule drug for the intratumoral treatment of solid tumors, inducing tumor cell death and stimulating immune response.
Pharmacy Times
FEBRUARY 16, 2024
The complexity of the disease and number of treatment options can necessitate a personalized approach.
Pharmacy Times
FEBRUARY 15, 2024
Sustained cognitive improvement is likely a result of lower inflammation, remission of comorbidities, higher physical activity, and better mood.
Pharmacy Times
FEBRUARY 15, 2024
Nutrition is foundational to health, but healthy eating does not look the same for everyone.
Pharmacy Times
FEBRUARY 15, 2024
Since the first FDA biosimilar approval of filgrastim-sndz (Zarxio) in 2015, a total of 44 biosimilars for 15 originator products have been approved and more than 20 are marketed.
Pharmacy Times
FEBRUARY 15, 2024
GLP-1 agonists are particularly challenging, given their high demand and costs.
Pharmacy Times
FEBRUARY 15, 2024
The meeting provided a brief overview of California's new Stop Dangerous Pharmacies Act, the benefits of e-prescribing for improving patient safety and outcomes, and New Jersey's pilot program for anonymous dispensing of opioid antidotes from pharmacies.
Pharmacy Times
FEBRUARY 6, 2024
Addressing complacency, confidence, and convenience are all crucial to increasing vaccine uptake.
Pharmacy Times
FEBRUARY 6, 2024
This breathing pattern is called resonant breathing and has been shown to improve heart rate variability.
Pharmacy Times
JANUARY 18, 2024
Despite the insignificant differences in efficacy, biomarkers, therapeutic drug level, and ADAs, patients reported a significant number of nocebo effects.
Pharmacy Times
JANUARY 18, 2024
The use of adulterated cannabinoids mixed with insecticides is becoming more common.
Pharmacy Times
JANUARY 18, 2024
The researchers found that the genomic material was extremely sensitive to the degradation.
Pharmacy Times
JANUARY 17, 2024
Experts discuss obstacles faced during transitioning myelofibrosis patients from inpatient to outpatient care, emphasizing communication, access to medication, and the need for standardized medication reconciliation protocols.
Pharmacy Times
JANUARY 17, 2024
Robert Mancini, PharmD, and Victoria Nachar, PharmD, discuss strategies and resources for smooth inpatient to outpatient transitions in myelofibrosis care, highlighting medication reconciliation, financial assistance, and the need for dedicated support staff.
Pharmacy Times
JANUARY 9, 2024
The accepted sBLA comes after phase 3 clinical trial results which demonstrated better overall survival, progression-free survival, and confirmed overall response rate than chemotherapy in patients with cervical cancer.
Pharmacy Times
JANUARY 9, 2024
In the ambulatory setting, oncology pharmacists independently prescribe medications to support and manage therapy toxicities for cancer patients.
Pharmacy Times
JANUARY 9, 2024
Studies have shown that higher expression of CYP2D6 alleles in adults results in excessive production of active metabolites, leading to either therapeutic failure, increased exposure, or more severe adverse effects.
Pharmacy Times
JANUARY 9, 2024
Patients who received telemedicine alone had worse glycemic control and less improvement in hemoglobin A1c levels.
Pharmacy Times
JANUARY 9, 2024
Experts explore early outcomes and patient candidacy factors for bispecific antibody therapy in diffuse large B-cell lymphoma (DLBCL) and discuss responses, real-world evidence, trends in patient outcomes, and selection biases.
Pharmacy Times
DECEMBER 22, 2023
One could also argue that the Great Resignation is an era for a great realignment. During lockdown, many individuals took the time to realign their priorities.
Pharmacy Times
DECEMBER 21, 2023
The biosimilars landscape is set to witness significant growth, particularly in therapeutic areas like ophthalmology and immunology, with a focus on blockbuster biologics like Humira, Stelara, and Eylea.
Pharmacy Times
DECEMBER 21, 2023
Comprehensive medication reviews and drug interaction assessments are examples of clinical interventions
Pharmacy Times
DECEMBER 21, 2023
Overtime, children can outgrow food allergies, like milk and eggs—however, children with private insurance are more likely to outgrow allergies than those with public insurance.
Pharmacy Times
DECEMBER 21, 2023
These drugs have interesting mechanisms, unique use, or may support expanded indications in the future.
Pharmacy Times
DECEMBER 21, 2023
Tune in to this episode of Public Health Matters for a captivating exploration of global public health through the lens of a pharmacist and traveler.
Pharmacy Times
DECEMBER 13, 2023
A panel of experts explore the evolving role of specialty pharmacists in hemophilia care, including gene therapy, adherence strategies, and the transformative impact on patients' lives.
Pharmacy Times
DECEMBER 13, 2023
As President, Lennartz will focus on strengthening the overall health of Health Mart and Health Mart Atlas pharmacy members and elevating the role they play in people’s lives.
Pharmacy Times
DECEMBER 13, 2023
Immune cells in lung cancer are connected to allergic conditions found in eczema and asthma.
Pharmacy Times
DECEMBER 13, 2023
Prefilled diluent and vaccine syringes may be easily mixed up
Pharmacy Times
DECEMBER 13, 2023
Christina Madison, PharmD, FCCP, AAHIVP, sat down with Noha Aboelata, MD to discuss her journey opening clinics and importance of health equity.
Pharmacy Times
DECEMBER 13, 2023
In the phase 3 SURMOUNT-4 trial, investigators included individuals with at least 1 weight-related complication, including hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.
Pharmacy Times
DECEMBER 13, 2023
Fractional COVID-19 dosing resulted in fewer adverse effects and costs while producing similar immune responses compared to a full dose vaccine.
Pharmacy Times
DECEMBER 5, 2023
Currently, there is no established standard of care treatment approach of HGBL, with frontline interventions consisting of chemo-immunotherapies.
Pharmacy Times
DECEMBER 4, 2023
Jennifer N.
Pharmacy Times
DECEMBER 4, 2023
Pirtobrutinib is the first and only non-covalent BTK inhibitor to be approved by the FDA and is indicated for adult patients who already received at least 2 prior lines of therapy.
Pharmacy Times
NOVEMBER 9, 2023
With this approval, fruquintinib is the first and only selective inhibitor of all 3 VEGR receptor kinases to be approved in the United States for previously treated mCRC, regardless of biomarker status.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content